Peptide Receptor Radionuclide Therapy, or lutetium PRRT, is a type of targeted radionuclide therapy used to treat some neuroendocrine tumours. It makes use of lutetium-177 (Lu-177), a radioactive compound that is bound to a peptide molecule and specifically targets receptors on the surface of neuroendocrine tumour cells.

Rare, slow-growing tumours that develop from cells in the endocrine and neurological systems are known as neuroendocrine tumours. On their cell surface, they frequently have high somatostatin receptor expression. By delivering a radioactive payload specifically to the tumour cells with lutetium PRRT, the malignant cells are destroyed with precision while causing the least amount of harm to healthy tissues.